Z-213 + Saccharated Ferric Oxide
Phase 3Completed 0 watching 0 views this week๐ Rising
76
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Iron Deficiency Anemia
Conditions
Iron Deficiency Anemia
Trial Timeline
May 1, 2016 โ Jan 1, 2018
NCT ID
NCT02731534About Z-213 + Saccharated Ferric Oxide
Z-213 + Saccharated Ferric Oxide is a phase 3 stage product being developed by Zeria Pharmaceutical for Iron Deficiency Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02731534. Target conditions include Iron Deficiency Anemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02731534 | Phase 3 | Completed |
Competing Products
20 competing products in Iron Deficiency Anemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KER-047 | Keros Therapeutics | Phase 2 | 44 |
| H. pylori treatment | Eisai | Phase 2/3 | 65 |
| Deferasirox | Novartis | Phase 3 | 77 |
| CSJ137 + Placebo | Novartis | Phase 1 | 33 |
| Deferasirox and Deferoxamine | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Phase 2 | 52 |
| ICL670 | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Approved | 85 |
| Deferasirox + Deferasirox | Novartis | Phase 2/3 | 65 |
| Desferasirox | Novartis | Approved | 85 |
| Deferasirox | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Phase 3 | 77 |
| Deferasirox dispersible tablet + Defearisox film-coated tablet | Novartis | Phase 2 | 52 |
| deferasirox | Novartis | Approved | 85 |
| Deferasirox (ICL670) | Novartis | Phase 1/2 | 41 |
| ICL670 | Novartis | Approved | 85 |
| Deferasirox | Novartis | Phase 3 | 77 |
| Core Study: Deferasirox + Core Study: Deferoxamine + Extension: deferoxamine to deferasirox + Extension: deferasirox to deferoxamine + Deferasirox + Deferoxamine | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Approved | 85 |
| Z-213 | Zeria Pharmaceutical | Phase 3 | 76 |